{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:38:27Z","timestamp":1790933907677,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848101007"],"award-info":[{"award-number":["848101007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejca.2023.02.017","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T19:28:37Z","timestamp":1677266917000},"page":"167-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma"],"prefix":"10.1016","volume":"185","author":[{"given":"Laurens\u00a0S.","family":"ter Maat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella A.J.","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Leiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran R.A.N.","family":"Arntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max F.","family":"Troenokarso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke A.M.","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Isgum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine A.","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franchette W.P.J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn F.","family":"Boomsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fons J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djura","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Art","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josien\u00a0P.W.","family":"Pluim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karijn P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitko","family":"Veta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.02.017_bib1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.017_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2023.02.017_bib3","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma","volume":"23","author":"Barone","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.02.017_bib4","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/1078-0432.CCR-16-0714","article-title":"FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma","volume":"23","author":"Beaver","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.02.017_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CJI.0000000000000334","article-title":"Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study","volume":"43","author":"van Zeijl","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2023.02.017_bib6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and Ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.02.017_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082329","article-title":"Real world outcomes of Ipilimumab and Nivolumab in patients with metastatic melanoma","volume":"12","author":"Asher","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.02.017_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.02.017_bib9","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.02.017_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000945","article-title":"Lower risk of severe checkpoint inhibitor toxicity in more advanced disease","volume":"5","author":"Verheijden","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2023.02.017_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.017_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041003","article-title":"Healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs","volume":"12","author":"Leeneman","year":"2020","journal-title":"Cancers"},{"issue":"128","key":"10.1016\/j.ejca.2023.02.017_bib13","first-page":"1","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1200\/JCO.21.01701","article-title":"Clinical models to define response and survival with anti\u2013PD-1 antibodies alone or combined with Ipilimumab in metastatic melanoma","volume":"40","author":"da Silva","year":"2022","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.ejca.2023.02.017_bib15","first-page":"1","article-title":"Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden","volume":"6","author":"Morrison","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1078-0432.CCR-20-2415","article-title":"Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma","volume":"27","author":"Johannet","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2023.02.017_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2023.02.017_bib18","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1118\/1.2207129","article-title":"Computer-aided diagnosis of pulmonary nodules on CT scans: Segmentation and classification using 3D active contours","volume":"33","author":"Way","year":"2006","journal-title":"Med Phys"},{"key":"10.1016\/j.ejca.2023.02.017_bib19","article-title":"Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach","volume":"5","author":"Aerts","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2023.02.017_bib20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00234-015-1576-7","article-title":"Somatic mutations associated with MRI-derived volumetric features in glioblastoma","volume":"57","author":"Gutman","year":"2015","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ejca.2023.02.017_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2022.07.034","article-title":"Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review","volume":"175","author":"ter Maat","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdz108","article-title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","volume":"30","author":"Trebeschi","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2023.02.017_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122992","article-title":"Combination of whole-body baseline CT radiomics and clinical parameters to predict response and survival in a stage-IV melanoma cohort undergoing immunotherapy","volume":"14","author":"Peisen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.02.017_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003261","article-title":"A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma","volume":"9","author":"Brendlin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/RLI.0000000000000180","article-title":"Measuring CT scanner variability of radiomics features","volume":"50","author":"Mackin","year":"2015","journal-title":"Investig Radiol"},{"key":"10.1016\/j.ejca.2023.02.017_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib27","doi-asserted-by":"crossref","unstructured":"Pieper S, Halle M, Kikinis R: 3D Slicer, in: Proceedings of the 2004 2nd IEEE Int. Symp. Biomed. Imaging Nano Macro IEEE Cat No 04EX821. 2004; Vol. 1:p. 632-635. \u3008https:\/\/doi.org\/10.1109\/ISBI.2004.1398617\u3009.","DOI":"10.1109\/ISBI.2004.1398617"},{"key":"10.1016\/j.ejca.2023.02.017_bib28","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.02.017_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.02.026","article-title":"Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study","volume":"167","author":"van Not","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ejca.2020.11.028","article-title":"Survival outcomes of patients with advanced melanoma from 2013 to 2017: results of a nationwide population-based registry","volume":"144","author":"van Zeijl","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.017_bib32","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1214\/15-EJS1035","article-title":"Computationally efficient confidence intervals for cross-validated area under the ROC curve estimates","volume":"9","author":"LeDell","year":"2015","journal-title":"Electron J Stat"},{"key":"10.1016\/j.ejca.2023.02.017_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/bjs.9736","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD statement","volume":"102","author":"Collins","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2023.02.017_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaoncol.2021.6818","article-title":"Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis","volume":"8","author":"Dercle","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.02.017_bib35","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.20.00995","article-title":"Five-year outcomes with Nivolumab in patients with wild-type BRAF advanced melanoma","volume":"38","author":"Robert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.017_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1109\/MSP.2019.2900993","article-title":"From handcrafted to deep-learning-based cancer radiomics: challenges and opportunities","volume":"36","author":"Afshar","year":"2019","journal-title":"IEEE Signal Process Mag"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:27Z","timestamp":1760733627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":36,"alternative-id":["S0959804923001090"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}